Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Since 2011, drug overdose has been the leading cause of accidental death in the United States, with two-thirds of these deaths related to opioid drugs. In 2020, the CDC reported an increase of over 91,000 overdose-related deaths. Also, non-fatal overdoses face a 5.5% one-year mortality rate post discharge, with a significant portion subsequently overdosing within 48 hours.
Access to Buprenorphine/Medication-Assisted Treatment (MAT) has been instrumental in reducing opioid-related mortality by over two-thirds, yet treatment initiation remains significantly low. Limited access stems from socioeconomic disparities and insufficient substance use treatment resources.
Emergency departments (EDs) have pioneered Buprenorphine inductions, showcasing variable success depending on post-ED support availability. Prehospital Buprenorphine administration, initiated across the country, aims to bridge the gap between prehospital care and traditional substance abuse treatment, enhancing treatment retention and patient engagement.
Studies highlight successful ED Buprenorphine inductions and subsequent linkage to long-term care, utilizing various strategies such as MAT prescriptions, Clinical Decision Units, and direct referrals to treatment centers. Despite retention to treatment, concerns arise regarding declining long-term retention and smaller sample sizes affecting outcomes.
Unexpectedly, these interventions have led to increased physician interest in Buprenorphine waiver applications and heightened ED encounters for substance use disorders. Notably, resident physicians have shown more engagement compared to attending physicians in out-of-hospital Buprenorphine prescriptions.
The review shows efforts in improving opioid use disorder treatment by leveraging prehospital and ED interventions, addressing access barriers, improving retention rates, and fostering physician engagement.
Keywords
Addiction, Opioid-Related Disorders, Buprenorphine, Medication Assisted Treatment, Opiate Substitution Treatment, Emergency Medical Services
Disciplines
Behavioral Medicine | Chemicals and Drugs | Emergency Medicine | Health and Medical Administration | Investigative Techniques | Medicine and Health Sciences | Substance Abuse and Addiction
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.142_2024
Included in
Behavioral Medicine Commons, Chemicals and Drugs Commons, Emergency Medicine Commons, Health and Medical Administration Commons, Investigative Techniques Commons, Substance Abuse and Addiction Commons
Bridging Gaps in Opioid Use Disorder Treatment: Prehospital and Emergency Department Interventions
Since 2011, drug overdose has been the leading cause of accidental death in the United States, with two-thirds of these deaths related to opioid drugs. In 2020, the CDC reported an increase of over 91,000 overdose-related deaths. Also, non-fatal overdoses face a 5.5% one-year mortality rate post discharge, with a significant portion subsequently overdosing within 48 hours.
Access to Buprenorphine/Medication-Assisted Treatment (MAT) has been instrumental in reducing opioid-related mortality by over two-thirds, yet treatment initiation remains significantly low. Limited access stems from socioeconomic disparities and insufficient substance use treatment resources.
Emergency departments (EDs) have pioneered Buprenorphine inductions, showcasing variable success depending on post-ED support availability. Prehospital Buprenorphine administration, initiated across the country, aims to bridge the gap between prehospital care and traditional substance abuse treatment, enhancing treatment retention and patient engagement.
Studies highlight successful ED Buprenorphine inductions and subsequent linkage to long-term care, utilizing various strategies such as MAT prescriptions, Clinical Decision Units, and direct referrals to treatment centers. Despite retention to treatment, concerns arise regarding declining long-term retention and smaller sample sizes affecting outcomes.
Unexpectedly, these interventions have led to increased physician interest in Buprenorphine waiver applications and heightened ED encounters for substance use disorders. Notably, resident physicians have shown more engagement compared to attending physicians in out-of-hospital Buprenorphine prescriptions.
The review shows efforts in improving opioid use disorder treatment by leveraging prehospital and ED interventions, addressing access barriers, improving retention rates, and fostering physician engagement.